Reviewed by Danielle Ellis, B.Sc.Sep 11 2023 But patients with an epidermal growth factor receptor gene mutation have not seen the same survival benefit.
Researchers analyzed data from 22 medical institutions, where patients with stage III NSCLC were treated between 2015 and 2022. Out of the 89 patients with the EGFR genetic mutation, those who received chemoradiation followed by EGFR TKI therapy lived longer, compared to those who received durvalumab after chemoradiation, or patients who had no additional treatment.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: